Dr Lisa Holland
Contact information
Lisa Holland
PhD
Research Facilitator
Lisa is Research Facilitator for the Mexico City Prospective Study – a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
She joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2006 as a member of the Vascular Overviews Group. Lisa worked on the meta-analyses of clinical trials of statins (Cholesterol Treatment Trialists Collaboration), of non-steroidal anti-inflammatory drugs (Coxib and NSAID Trialists Collaboration), and of angiotension receptor blockers for the treatment of Marfan Syndrom.
Lisa Holland completed an undergraduate degree in Biochemistry with Microbiology at Lancaster University and a PhD in Molecular Microbiology at the University of Nottingham.
Recent publications
-
Alcohol and mortality in Mexico: prospective study of 150 000 adults.
Journal article
Trichia E. et al, (2024), Lancet Public Health, 9, e907 - e915
-
Blood Pressure, eGFR, and Kidney Mortality in Mexico: A Prospective Study of 150,000 Adults
Journal article
Zhu D. et al, (2024), Journal of the American Society of Nephrology, 35
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
-
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
-
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Journal article
Pitcher A. et al, (2022), Lancet